AU2005228856A1 - Pyrazole compounds and uses related thereto - Google Patents

Description

WO 2005/095350 PCT/US2005/009292 PYRAZOLE COMPOUNDS AND USES RELATED THERETO CROSS-REFERENCES TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application Ser. No. 5 60/556,013, filed March 23, 2004, the content of which is incorporated herein by reference. STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] NOT APPLICABLE 10 REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK. [0003] NOT APPLICABLE 15 BACKGROUND OF THE INVENTION [0004] The present invention relates to pyrazole compounds having HSD1 inhibitory activity. 11-Beta-hydroxysteroid dehydrogenase 1 (hereinafter, "1l#--HSD1" or "HSD1") catalyzes the interconversion of glucocorticoids (hereinafter, "GC") between inert 11 -keto forms (e.g. cortisone, 11 -dehydrocorticosterone) and active 1 lfl-hydroxy forms (e.g. cortisol, 20 corticosterone, respectively). The enzyme, in vivo, prefers the reductase direction from 11 keto to 110 -hydroxy, in other words, the production of active GC. [0005] 1 1-HSD1 is ubiquitously expressed, most notably in liver, lung, adipose tissue, vasculature, ovary and the central nervous system. [0006] Recently, experimental results have suggested that the active form of GC produced 25 through HSD 1 as well as the enzyme itself is involved in several biological actions and diseases. [0007] For example, the active GC is known to stimulate gluconeogenic enzymes and have effects at least in part in inducing hyperglycemia. In this situation, HSD1 can be a second source of GC production in addition to the adrenal glands. 1 WO 2005/095350 PCTIUS2005/009292 [0008] As another example, continuous excess of the active GC in peripheral tissues, as observed in Cushing's syndrome, leads to insulin resistance, where HSD1 is considered to have an important role. [0009] Also, in adipose tissue, active GC has been demonstrated to enhance the 5 differentiation of preadipocytes into adipocytes. Mature adipocytes express HSD1 activity, which causes an increase in local concentration of the active form and further expansion of adipose tissue. Such an action of HSD1 should be critical in pathogenesis of obesity. [00101 In addition, a local immunosuppressive effect of HSD1 in placental deciduas, and a relationship between the expression of the enzyme in adrenal cortex and the induction of 10 adrenaline synthesis, have been suggested. 10011] (The above are referred to in: Quinkler M, Oelkers W & Diederich S (2001) European Journal of Endocrinology Vol. 144, Pages 87-97; and Seckl JR & Walker BR (2001) Endocrinology Vol. 142, Pages 1371-1376.) [0012] According to the above suggestions, it is expected that drugs having inhibitory 15 effects against HSD1 would be useful for treating or preventing diabetes mellitus, obesity, metabolic syndrome in connection with any of such diseases, or any other diseases which occur by reason of the actions of HSD1. [00131 Diabetes mellitus, the main feature of which disease is chronic hyperglycemia, introduces various metabolic abnormalities and shows symptoms of thirst, polydipsia, 20 polyuria, and so on based on high glucose concentration. A continuing hyperglycemic state can also lead to diabetic complications such as retinopathy, nephropathy, neuropathy, and myocardial and/or cerebral infarction by reason of arteriosclerosis. [0014] In treating diabetes, moderate suppression of hyperglycemia is critical in order that onset and progress of the complications would be repressed. For these purposes, dietetics, 25 ergotherapy and pharmacotherapy are utilized in combination on a suitable basis and, amongst the pharmacotherapy, many approaches different in mechanisms of action have been attempted. In spite of those various existing methods, sufficient therapeutic effect has not ever been achieved. [00151 Obesity is defined as a state of fatness coinciding with any disease that would be 30 improved or not be progressed in case of weight decrease (e.g. diabetes, hyperlipidemia, hypertension) or with an excessive amount of fat in viscera. It is considered that, if such a 2 WO 2005/095350 PCTIUS2005/009292 state should continue, at least two of diabetes, hyperlipidemia, hypertension and related disorders would concur, followed by the onset of myocardial and/or cerebral infarction by reason of arteriosclerosis. [00161 Major therapeutic methods in treating obesity are dietetics and ergotherapy, and 5 pharmacotherapy is undertaken only if necessary, for example, because of difficulty in the first two alternatives. However, the existing drugs have several problems in adverse effects and usages, since most of them suppress feeding mainly via central action. [0017] In consequence, development of any drug to treat diabetes and/or obesity with a novel mechanism of action has so far been required. Under these circumstances, it is 10 expected that drugs having inhibitory effects against HSD 1 would be useful as another alternative with separate mechanistic approach to treat diabetes mellitus, as well as a novel "adipose tissue-acting" class among other drugs against obesity. [00181 As drugs in development to treat diabetes and/or obesity through inhibition of HSD1, for example, WO 03/104207 and WO 03/104208 disclose triazole compounds of the 15 following general formula: N-N (R1)3 N

R

3 A B 2 wherein: [00191 A and B are taken separately or together; [00201 when taken separately, A is halo, unsubstituted or substituted Ci- 6 alkyl, 20 unsubstituted or substituted OC1.

6 alkyl or unsubstituted or substituted phenyl and B is -H, halo, unsubstituted or substituted C 1

.

6 alkyl, unsubstituted or substituted OCI 6 alkyl, unsubstituted or substituted -SC 1

.

6 alkyl, unsubstituted or substituted C 2

.

6 alkenyl, unsubstituted or substituted phenyl or unsubstituted or substituted naphthyl; and [00211 when taken together, unsubstituted or substituted C1 4 alkylene or unsubstituted or 25 substituted C 2

-

5 alkanediyl; [00221 each R1 is -H, -OH, halo, unsubstituted or substituted C 1

..

1 oalkyl, unsubstituted or substituted CI 6 alkoxy or unsubstituted or substituted C&.

1 oaryl, or two R 1 taken together are a fused Cs- 6 alkyl (either unsubstituted or substituted) or unsubstituted or substituted aryl ring; 3 WO 2005/095350 PCT/US2005/009292 [0023] R 2 and R 3 are taken separately or together; [0024] when taken together, (a) a C 3

.

8 alkanediyl forming a fused 5-10 membered non aromatic ring (optionally interrupted with 1-2 double bonds, either unsubstituted or substituted) or (b) a fused 6-10 membered aromatic monocyclic (either unsubstituted or 5 substituted) or bicyclic group (either unsubstituted or substituted); [0025] when taken separately, R 2 is C1.14 alkyl (either unsubstituted or substituted), unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, either unsubstituted or substituted C 2 -10 alkenyl, -CH 2

CO

2 H, -CH 2

CO

2

C

1

.

6 alkyl, -CH 2 C(O)NHRa, -NH2, -NHa or N(Ra) 2 and R 3 is unsubstituted or substituted C1 4 alkyl, unsubstituted or substituted C 2 10 1 oalkenyl, unsubstituted or substituted SC 1

.

6 alkyl, unsubstituted or substituted C6-ioaryl, unsubstituted or substituted heterocyclyl or unsubstituted or substituted heteroaryl; [0026] Ra is unsubstituted or substituted C 1

-

3 alkyl, unsubstituted or substituted OC 1

-

3 alkyl, unsubstituted or substituted C 6

.

1 0 ArC 1

.

6 alkylene or unsubstituted or substituted phenyl; [00271 However, the description provided in the noted applications does not disclose or 15 suggest any of the compounds having the structure of the present invention. [0028] The compounds of the present invention improve physicochemical (stability, etc.) and biological (activity to inhibit HSD1, specificity, bioavailability, metabolism, etc.) profiles, as a result of the selection of structural characteristics as disclosed herein. 20 BRIEF SUMMARY OF THE INVENTION [0029] According to the present invention, it has been found that pyrazole compounds represented by the following formula have superior HSD1 inhibitory activity, and are useful as HSD1 inhibitors or therapeutic drugs for the treatment of diabetes or obesity. [0030] The present invention provides the following: 25 [0031] In one aspect, the present invention provides pyrazole compounds represented by the following formula: R8 N-N Ar 2 A

R

9 m Ar'

R

4

R

5

R

1

R

2

R

3 4 WO 2005/095350 PCTIUS2005/009292 wherein [0032] R' is a hydrogen atom, -CO-O-alkyl, -COOH, an alkyl group, an alkoxy group or a cycloalkyl group, wherein the alkyl group, the alkoxy group and the cycloalkyl group are optionally substituted by 1 to 5 substituents each independently selected from a halogen 5 atom, a haloalkyl group, -OH, -NH 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(Ri 0

)(R

1 ), -N(R1 0

)-CO-R

1 , an aryl group and a heteroaryl group, wherein R1 0 and R 1 are each independently a hydrogen atom or an alkyl group, and the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )h-OH, 10 -N(R 12 )(RII), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R1 4 , an aryl group and a heteroaryl group, wherein h is 0-3, R and R 1 are each independently a hydrogen atom, an alkyl group or -CO-alkyl, and R 1 4 is -OH, an alkoxy group, an alkyl group or -N(R1 5 )(R1 6 ), wherein R 15 and R 16 are each independently a hydrogen atom or an alkyl group; 15 [00331 R2, R , R and R5 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a cycloalkyl group or R2 and R3, and/or R 4 and R5 in combination with the carbon atoms to which they are attached form a ring represented by

Y

1 wherein the Y' ring is a cycloalkane or a heterocycloalkane group, the wavy lines indicate the 20 point of attachment to the remainder of the molecule and wherein the cycloalkane group and the heterocycloalkane group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )h-OH,

-N(R'

2

)(R

3 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 4 , an aryl group and a heteroaryl group (h, R1 2 , R" and R1 4 are as defined above), 25 [0034] wherein the alkyl group, the alkoxy group and the cycloalkyl group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(R1 0 )(R"), an aryl group and a heteroaryl group 5 WO 2005/095350 PCTIUS2005/009292 [0035] wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )h-OH, -N(R1 2 )(RII), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group and a heteroaryl group (R1 0 , R 1 1, h, R 2 , R" and R 1 4 5 are as defined above); [0036] the subscript n is an integer of from 0 to 3; [0037] Ar is an aryl group or a heteroaryl group; [0038] R 6 and R7 are each independently a hydrogen atom, a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )r-OH, -N(R1 2

)(RI

3 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl 10 group, an alkenyl group, -CO-R 4 , an aryl group or heteroaryl group, wherein j is 0-3, and the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )h-OH, -N(R1 2

)(R

3 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 4 , an aryl group and a heteroaryl group (R", R 13 , R1 4 and h are as defined above); 15 [0039] the subscript in is an integer of from 0 to 3; [0040] R 8 and R 9 are each independently a hydrogen atom, a halogen atom, -OH, -NO 2 , -CN, an alkyl group, an alkoxy group, -CO-R 17 , -S0 2

-R

7 , -CO-N(R")(R 9 ), -N(R 20 )(R ) or in combination form -O-alkylene-O-, wherein the alkyl group and the alkoxy group are optionally substituted by 1 to 5 substituents each independently selected from a halogen 20 atom, a haloalkyl group, -OH, -NH 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(Rl 0 )(R"), -N(R1 0 )-CO-R", an aryl group and a heteroaryl group, wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )h-OH, -N(R1 2 )(R1 3 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an 25 alkenyl group, -CO-R14, an aryl group and a heteroaryl group (R10, R", h, R1 2 , R 13 and R 1 5 are as defined above), [0041] R 17 is -OH, an alkoxy group, an alkyl group, -NH 2 , -NH-alkyl or -N(-alkyl) 2 , wherein the alkoxy group and alkyl groups are optionally substituted by substituents each independently selected from -OH, -SO 2

-R

2 and -(CH 2 )t-CO-R 3 , wherein t is 0-3, R 2 is an 30 alkyl group or -NH 2 , and R 23 is an alkyl group, -NH-alkyl, -N(-alkyl) 2 , or -NH 2 , wherein the alkyl groups are optionally substituted by substituents each independently selected from -OH, 6 WO 2005/095350 PCTIUS2005/009292 an alkoxy group or -(CH 2

)

1

-N(R

24 )(Re 5 ), wherein u is 0-3, and R 2 4 and R 2 5 are each independently a hydrogen atom, an alkyl group or -CO-alkyl, [0042] R" and R" are each independently a hydrogen atom, an alkyl group or -(CH2)p-R26 wherein p is 0-3 and R 6 is -OH, a haloalkyl group, an alkoxy group, -CO-NH 2 or 5 -N(R 24

)(R

25 ), wherein R 24 and R 25 are as defined above; [0043] R 20 and R' are each independently a hydrogen atom, an alkyl group -CO-R 3 or in combination with the nitrogen atom to which each is attached, form

SR

28 wherein the alkyl group is optionally substituted by substituents each independently selected 10 from -OH, -S0 2

-R

2 and -(CH 2 )t-CO-R (wherein R 2 and R 23 are as defined above), X 1 is -CO-, -CH 2 - or -CH 2

-CH

2 -, X2 is -0-, -(CH2)q- or -N(R 9 )- or a spirocyclic ring represented by Y2 wherein q is 0-2, R 9 is a hydrogen atom, -CO-R 30 , -S0 2

-R

30 or -(CH 2 )r-Ar 3 , wherein R3 0 is 15 an alkyl group, an alkoxy group, -NH-alkyl or -N(-alkyl) 2 , r is 0-3, and Ar 3 is an aryl group or heteroaryl group, wherein the aryl group and heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )h-OH, -N(R12)(R ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 14, an aryl group and a heteroaryl group (h, R 12 , R" and R1 4 are as 20 defined above), and the spirocyclic Y 2 ring is a spiro-cycloalkyl or spiro-heterocycloalkyl ring, and R 7 and R 8 are each independently a hydrogen atom, a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )h-OH, -N(R1 2

)(R

3 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R14, an aryl group or a heteroaryl group (h, R 12 , R1 3 and R1 4 are as defined above); 25 [0044] Ar 2 is an aryl group, a heteroaryl group or a ring having the formula 7 WO 2005/095350 PCTIUS2005/009292 / \ --Vi W 1 x3 _/, wherein V1 is CH or N, X 3 is -(CH 2 )v-, wherein v is 0-2, and W1 is -C(R)(R 32 )-, -CO- or

-N(R

33 )-, wherein R" and R 32 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, -(CH 2 )wv-OH, -CO-R 3 4 , -L'-Ar 4 or -N(R 35

)

36 ), wherein w 5 is 0-3, R 34 is -OH, an alkoxy group, an alkyl group or -N(R 7 )(R), wherein R" and R" are each independently a hydrogen atom, an alkyl group, -(CH 2 )-OH or an alkoxy group, wherein x is 0-3, L' is -(CH 2 )y-, -0- or -CO-, wherein y is 0-3, Ar is an aryl group or a heteroaryl group, wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an 10 alkyl group, -(CH 2 )h-OH, -N(R' 2 )(R1 3 ), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 1 4 , an aryl group and a heteroaryl group (h, R 12 , R 13 and R 1 4 are as defined above), and R? 5 and R 36 are each independently a hydrogen atom, an alkyl group, -CO-alkyl, -CO-O-alkyl or L'-Ar 4 (L' and Ar 4 are as defined above), and R 33 is a hydrogen atom, -CO-R 28 , -SO 2

-R

2 8 or -(CH 2 )k-Ar 3 , wherein k is 0-3 (R 28 and Ar 3 are as defined above); 15 and [0045] the pyrazole ring (labeled A) provided as N-N A R' is selected from H N-NH N-N / and R1 20 [00461 or a prodrug thereof or a pharmaceutically acceptable salt thereof. [0047] In the above compounds of the invention, any variable used to define another variable is meant to have its most complete meaning as-provided above, unless otherwise stated. Additionally, when a letter subscript is provided with a range (e.g., x and y being 0 to 3), the lower limit (0) is meant to indicate the presence of a bond.

WO 2005/095350 PCTIUS2005/009292 [00481 In some embodiments, the pyrazole compound has the formula above, wherein the subscript m is 0, a prodrug thereof or a pharmaceutically acceptable salt thereof. [0049] In other embodiments, the pyrazole compound has the formula above, wherein the subscript m is 0, and where R 2 and R3 are in combination with the carbon atom to which they 5 are attached to form

Y

1 wherein the Y' ring is a C 3

.

8 cycloalkane group, and the compounds further include a prodrug thereof or a pharmaceutically acceptable salt thereof. Within this group of embodiments, preferably Ar' is an phenyl group. Still further preferred are those embodiments in which R 6 10 and R7 are each independently a halogen atom or a hydrogen atom. [00501 In another aspect, the present invention provides a pharmaceutical composition comprising one or more of the pyrazole compounds described above, a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. [0051] In yet another aspect, the present invention provides a HSD1 (110-hydroxysteroid 15 dehydrogenase 1) inhibitor comprising a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component. [0052] In a related aspect, the present invention provides a therapeutic or prophylactic drug for diabetes, which comprises a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component. 20 [00531 In another aspect, the present invention provides a therapeutic or prophylactic drug for obesity, which comprises a pyrazole compound as described above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component. [00541 In yet another aspect, the present invention provides a therapeutic or prophylactic drug for metabolic syndrome, which comprises a pyrazole compound as described above, a 25 prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component. [0055] In still another aspect, the present invention provides a method for the treatment or prophylaxis of diabetes, which comprises administering an effective amount of a pyrazole 0 WO 2005/095350 PCTIUS2005/009292 compound described above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal. [0056] In another aspect, the present invention provides a method for the treatment or prophylaxis of obesity, which comprises administering an effective amount of a pyrazole 5 compound described above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal. [00571 In yet another aspect, the present invention provides a method for the treatment or prophylaxis of metabolic syndrome, which comprises administering an effective amount of a pyrazole compound described above, a prodrug thereof or a pharmaceutically acceptable salt 10 thereof to a mammal. [0058] In still another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above, in combination with a different therapeutic drug for the treatment of diabetes. Preferably, the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the 15 group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an a-glucosidase inhibitor, a PTP1B inhibitor and an insulin sensitizer. In other preferred embodiments, the different therapeutic drag for diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, 20 nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride. 10059] In another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above for obesity, which is used in combination with a different therapeutic drug for the treatment of diabetes. 25 Preferably, the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an a-glucosidase inhibitor, a PTP 1B inhibitor and an insulin sensitizer. In other preferred embodiments, the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, 30 glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride. 1 i WO 2005/095350 PCTIUS2005/009292 [00601 In yet another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above for metabolic syndrome, which is used in combination with a different therapeutic drug for the treatment of diabetes. Preferably, the different therapeutic drug for diabetes is one or more 5 pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an a-glucosidase inhibitor, a PTP lB inhibitor and an insulin sensitizer. In other preferred embodiments, the different therapeutic drug for diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, 10 glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride. [0061] In still another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above for diabetes, which is used in combination with a different therapeutic drug for the treatment of 15 obesity. Preferably, the different therapeutic drug for obesity is Mazindol. [0062] In another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use of a pyrazole compound as described above for obesity, which is used in combination with a different therapeutic drug for the treatment of obesity. Preferably, the different therapeutic drug for obesity is Mazindol. 20 [0063] In yet another aspect related to those above, methods are provided wherein a therapeutic regimen comprises the use-of a pyrazole compound as described above for metabolic syndrome, which is used in combination with a different therapeutic drug for the treatment of obesity. Preferably, the different therapeutic drug for obesity is Mazindol. 25 BRIEF DESCRIPTION OF THE DRAWINGS [0064] Not applicable. DETAILED DESCRIPTION OF THE INVENTION [0065] Compounds of the present invention have been described above. More specifically, 30 respective substituents and moieties used in the present specification are defined in the following. 1 1 WO 2005/095350 PCTIUS2005/009292 [0066] The "alkyl group" means a straight chain or branched chain alkyl group. Examples thereof include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, tert-pentyl group, 1-ethylpropyl group, hexyl group and the like. It is preferably a 5 straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms. [00671 For R', R 2 , R 3 , R , R 6 , R 7 , R 8 , R9, R 10 , R 11 , R 12 , R1 3 , R 14 , R1 5 , R1 6 , R1 7 , R1 8 , R1 9 ,

R

20 , RM, R 2 , R 23 , R 24 , R 25 , R 27 , R 28 , R 30 , R 31 , R 32 , R 34 , R, R 36 , R 37 and R 3 , preferred are methyl, ethyl, propyl, isopropyl, butyl and isobutyl, and particularly preferred are methyl and 10 isopropyl. [0068] The "cycloalkyl group" means a saturated cyclic alkyl group. Examples thereof include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group and the like. It is preferably a cycloalkyl group having 3 to 8, more preferably 3 to 6, carbon atoms. 15 [0069] For R', R 2 , R 3 , R 4 , R, R 6 , R 7 , R, R 28 , Y' and Y 2 , preferred are cyclopropyl, cyclobutyl and cyclopentyl, and particularly preferred is cyclopropyl. In the case of Y' and

Y

2 , the rings are attached in a spirocyclic manner to the remainder of the molecule. [0070] The "heterocycloalkyl group" means a saturated 5- to 7-membered heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, 20 oxygen atom and sulfur atom. Examples thereof include tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, pyrazolidinyl group, imidazolidinyl group, oxazolidinyl group, thiazolidinyl group, tetrahydropyranyl group, dioxolanyl group, dioxanyl group, piperidinyl group, piperazinyl group, morpholinyl group and the like. [0071] For Y 1 and Y2, preferred is piperidinyl, which in the case of the Y 2 ring is attached 25 in a spirocyclic manner to-the remainder of the molecule. [0072] The "alkenyl group" means a straight chain or branched chain alkenyl group. Examples thereof include vinyl group, 1-propenyl group, allyl group, 1-methyl-2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-pentenyl group, 2-pentenyl group, 1-hexenyl group, 2-hexenyl group and the like. It is preferably a straight chain or 30 branched chain alkenyl group having 2 to 6, more preferably 2 to 4, carbon atoms. [0073] For R 6 , R 7 , R 27 and R 28 , preferred is vinyl. 11, WO 2005/095350 PCTIUS2005/009292 [00741 The "aryl group" means an aromatic hydrocarbon group. Examples thereof include phenyl group, naphthyl group, anthryl group and the like. It is preferably a phenyl group or naphthyl group. [00751 For R', R7, R 2 7 , R 2 , Ar', Ar 2 , Ar 3 and Ar 4 , preferred are phenyl and naphthyl, and 5 particularly preferred is phenyl. [0076] The "heteroaryl group" means a monocyclic or fused 5- to 14-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom. Examples thereof include furyl group, thienyl group, pyrrolyl group, oxazolyl group, isooxazolyl group, thiazolyl group, isothiazolyl group, 10 imidazolyl group, pyrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, indolyl group, isoindolyl group, benzofuranyl group, benzothienyl group, benzoimidazolyl group, benzothiazolyl group, benzoxazolyl group, indolizinyl group, quinolyl group, isoquinolyl group, quinazolinyl group, cinnolinyl group, quinoxalinyl group, phthalazinyl group, acridinyl group, phenazinyl group, naphthyridinyl group and the like. It 15 is preferably a monocyclic or fused 5- to 10-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, which includes furyl group, thienyl group, pyrrolyl group, oxazolyl group, isooxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, indolyl group, 20 isoindolyl group, benzofuranyl group, benzothienyl group, benzoimidazolyl group, benzothiazolyl group, benzooxazolyl group and the like. [0077] For R 6 , R7, Ar', preferred are thienyl, pyrrolyl and pyridyl. [0078] For R- , R ', Ar 2 , preferred are thienyl, pyrrolyl, oxazolyl, isooxazolyl, thiazolyl, imidazolyl, pyrazolyl and pyridyl, and particularly preferred are thienyl and pyridyl. 25 [0079] -For Ar 3 and Ar 4 , preferred is pyridyl. [0080] The "halogen atom" means fluorine atom, chlorine atom, bromine atom or iodine atom. It is preferably fluorine atom or chlorine atom. [00811 For Ri and R, preferred is fluorine atom or chlorine atom. In this case, Ar' is particularly preferably phenyl, where only the 4-position of the phenyl is substituted by 30 fluorine atom or chlorine atom.

WO 2005/095350 PCTIUS2005/009292 [0082] For R 8 and R 9 , preferred is chlorine atom. In this case, Ar2 is particularly preferably phenyl, where at least the 2-position of the phenyl is substituted by chlorine atom. [0083] For R 7 and R 8 , preferred are fluorine atom or chlorine atom. [0084] The "haloalkyl group" means a haloalkyl group wherein the above-defined "alkyl 5 group" is substituted by the above-defined "halogen atom". Examples thereof include fluoromethyl group, difluoromethyl group, trifluoromethyl group, bromomethyl group, chloromethyl group, 1,2-dichloroethyl group, 2,2-dichloroethyl group, 2,2,2-trifluoroethyl group and the like. It is preferably a straight chain or branched chain haloalkyl group having 1 to 6, more preferably 1 to 4, carbon atoms, particularly preferably a trifluoromethyl group. 10 [0085] For R6, R,W R,R R , R and R 2 , preferred are fluoromethyl group, difluoromethyl group or trifluoromethyl group. [0086] The "alkoxy group" means a straight chain or branched chain alkoxy group. Examples thereof include methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, tert-butoxy group, pentyloxy group, hexyloxy group and the 15 like. It is preferably a straight chain or branched chain alkoxy group having 1 to 6, more preferably 1 to 4, carbon atoms. [00871 For R', R, R , R, R , R6, R7, R , R, R , R , R6, R7, R8, R30, RI, R32, R34, R3 and R ', preferred are methoxy, ethoxy and isopropoxy. [0088] The "-CO-alkyl" means an alkylcarbonyl group having the above-defined "alkyl 20 group" as the alkyl moiety. Examples thereof include acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, pentanoyl group, hexanoyl group and the like. It is preferably an alkylcarbonyl group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms. 25 [0089] For R , R", R4, R, R" and R 6 , particularly preferred are acetyl, propionyl, butyryl and isobutyryl. [0090] The "-CO-0-alkyl" means an alkoxycarbonyl group having the above-defined "alkyl group" as the alkyl moiety. Examples thereof include methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbonyl group, butoxycarbonyl 30 group, isobutoxycarbonyl group, sec-butoxycarbonyl group, tert-butoxycarbonyl group, WO 2005/095350 PCTIUS2005/009292 pentoxycarbonyl group, isopentoxycarbonyl group, neopentoxycarbonyl group, tert pentoxycarbonyl group, 1-ethylpropoxycarbonyl group, hexyloxycarbonyl group and the like. It is preferably an alkoxycarbonyl group wherein the "alkyl moiety" is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms. 5 [0091] For R 1 , RM and R 36 , particularly preferred are methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl and tert-butoxycarbonyl. [0092] The "-NH-alkyl" means an alkylamino group having the above-defined "alkyl group" as the alkyl moiety. Examples thereof include methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, isobutylamino group, sec 10 butylamino group, tert-butylamino group, pentylamino group, isopentylamino group, tert pentylarnino group, hexylamino group and the like. It is preferably an alkylamino group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms. [0093] For R" 7 , R and R 30 , particularly preferred are methylamino, ethylamino, 15 propylamino and isopropylamino. [0094] The "-N(-alkyl) 2 " means a dialkylamino group having the above-defined "alkyl group" as the alkyl moiety. Examples thereof include dimethylamino group, diethylamino group, dipropylamino group, diisopropylamino group, dibutylamino group, diisobutylamino group, di(sec-butyl)amino group, di(tert-butyl)amino group, dipentylamino group, 20 diisopentylamino group, di(tert-pentyl)amino group, dihexylamino group, N-ethyl-N methylamino group, N-methyl-N-propylamino group, N-ethyl-N-propylamino group and the like. It is preferably a dialkylamino group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms. [0095] For R", R and R 30 , particularly preferred are dimethylamino, diethylamino and N 25 ethyl-N-methylamino. [0096] The "alkyl group" and "alkoxy group" are optionally substituted by 1 to 5 substituents each independently selected from halogen atom, -CF 3 , -OH, alkoxy group, haloalkoxy group, -N(R 1

)(R

12 ) (Ru' and R 2 are each independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -NO 2 , cycloalkyl group, alkenyl group, -CO-R (R" is -OH, 30 alkoxy group, alkyl group or -N(R 14 )(R1 5 ) wherein R 14 and R 1 5 are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group. Here, the substituent "aryl 1 <z WO 2005/095350 PCTIUS2005/009292 group" and "heteroaryl group" are optionally substituted by 1 to 3 substituents each independently selected from halogen atom, haloalkyl group, alkyl group, -(CH 2 )-OH (n=0 3), -N(R 1

)(R'

2 ) (R1' and R1 2 are independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -NO 2 , alkoxy group, cycloalkyl group, alkenyl group, -CO-R1 3 (R" is -OH, alkoxy 5 group, alkyl group or -N(R14)(RI 5 ) wherein R 1 4 and R1 5 are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group. [00971 The "alkyl group" for R 17 , R 2 0 , R 1 and the "alkoxy group" for R 17 are optionally substituted by substituents each independently selected from -OH, -S0 2

-R

2

(R

2 is an alkyl group or -NH 2 , and R 3 is an alkyl group, -NH-alkyl, -N(-alkyl) 2 , or -NH 2 wherein the alkyl 10 groups are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH 2 )r-N(R 24

)(

25 )) (u is 0-3, R 24 and R 25 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH 2

)-CO-R

3 (t is 0-3). [0098] The alkyll group" for R 2 and R 3 are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH 2 )r-N(R 2 4

)(R

5 )) (u is 0-3, R 24 and 15 R are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH 2

)-CO

R

2 (t is 0-3). [0099] The "alkyl" moieties of the "haloalkyl group" for R 6 , R 7 , R 26 , R, R 28 , R 1 and R, "alkylcarbonyl group" for R 12 , R 13 , R 24 , R 5 , R 35 and R 36 , "alkyloxycarbonyl group" for R',

R

35 and R 3 6 , "alkylamino group" for R 30 and "dialkylamino group" for R 30 are optionally 20 substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N(Rio)(Ru) (R1 0 and R 10 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group. Here, the substituent "aryl group" and "heteroaryl group" are optionally substituted by 1 to 3 substituents each independently 25 selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )h-OH (h is 0-3),

-N(R

12

)(R

13 ) (R1 2 and R 13 are each independently a hydrogen atom, an alkyl group or -CO alkyl), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R1 4 (R1 4 is -OH, an alkoxy group, an alkyl group or -N(R 1 5 )(R1') wherein R 5 and R' 6 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group. 30 [0100] The "alkyl" moieties of the "alkylamino group" for R1 7 and "dialkylamino group" for R 17 are optionally substituted by substituents each independently selected from -OH, -S0 2 -R (R is an alkyl group or -NH 2 , and RM is an alkyl group, -NH-alkyl, -N(-alkyl) 2 , or 1 WO 2005/095350 PCTIUS2005/009292

-NH

2 wherein the alkyl groups are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(C1 2 )u-N(R 2 4

)(R

25 )) (u is 0-3, R 24 and R 5 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH 2 )t-CO-R (t is 0-3). [0101] The "alkyl" moieties of the "alkylamino group" for R 3 and "dialkylamino group" 5 for R 3 are optionally substituted by substituents each independently selected from -OH, an alkoxy group or -(CH 2 )u-N(R 2 4

)(

25 )) (u is 0-3, R 24 and R 5 are each independently a hydrogen atom, an alkyl group or -CO-alkyl) and -(CH 2 )t-CO-R 3 (t is 0-3). [01021 The "aryl group" and the "heteroaryl group" are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl 10 group, -(CH 2 )h-OH (h is 0-3), -N(R1 2 )(RII) (R1 2 and R" are each independently a hydrogen atom, an alkyl group or -CO-alkyl), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R 1 4

(R

1 4 is -OH, an alkoxy group, an alkyl group or -N(R 5

)(R'

6 ) wherein R' 5 and R1 6 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group. 15 [0103] The "cycloalkyl group" for R 6 , R 7 , R, R, Y' and Y 2 and "heterocycloalkyl group" for Y 1 and Y 2 are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )h-OH (h is 0-3),

-N(R

12 )(R1 3 ) (R1 2 and R1 3 are each independently a hydrogen atom, an alkyl group or -CO alkyl), -CN, -NO 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R1 4

(R

14 is 20 -OH, an alkoxy group, an alkyl group or -N(R 5 )(Ri) wherein R 1 5 and R 16 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group. [0104] The "cycloalkyl group" for R 1 , R 2 , R 3 , R 4 and R 5 are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, a haloalkyl group, -OH, -NH 2 , an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO 25 N(R 10 )(R1) (R10 and R" are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group. Here, the substituent "aryl group" and "heteroaryl group" are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH 2 )h-OH (h is 0-3), -N(R 1 2 )(R1 3 ) (R 12 and R1 3 are each independently a hydrogen atom, an alkyl group or -CO-alkyl), -CN, -NO 2 , an alkoxy 30 group, a cycloalkyl group, an alkenyl group, -CO-R1 4 (R1 4 is -OH, an alkoxy group, an alkyl group or -N(R 5 )(R1 6 ) wherein R 15 and R 16 are each independently a hydrogen atom or an alkyl group), an aryl group and a heteroaryl group. 17 WO 2005/095350 PCTIUS2005/009292 [0105] The above-mentioned substituents "alkyl group", "cycloalkyl group", "heterocycloalkyl group", "alkenyl group", "aryl group", "heteroaryl group", "halogen atom", "haloalkyl group", "alkoxy group", "haloalkoxy group" are as defined above. [01061 R' and R 9 in combination may form -O-alkylene-O-. Here, the "alkylene" means a 5 divalent hydrocarbon. Examples thereof include methylene, ethylene, propylene, butylene, pentylene, hexylene and the like. It is preferably an alkylene having 1 to 6, more preferably 1 to 4, carbon atoms, particularly preferably methylene. [0107] In the above-mentioned formulae, m is preferably 0; R 2 and R 3 are preferably in combination to form a Y 1 ring, which is a C 3

-

8 cycloalkane group; Arl is preferably a phenyl 10 group; R 6 and R are preferably independently a halogen atom or a hydrogen atom. [0108] The "pharmaceutically acceptable salt" may be any salt as long as it forms a non toxic salt with a pyrazole compound represented by the above-mentioned formula. For example, it can be obtained by reaction with inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; organic acids such as oxalic 15 acid, malonic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, benzylsulfonic acid and the like; inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonium hydroxide and the like; organic bases such as methylamine, diethylamine, triethylamine, triethanolamine, 20 ethylenediamine, tris(hydroxymethyl)methylamine, guanidine, choline, cinchonine, N methyl-D-glucamine and the like; or amino acids such as lysin, histidine, arginine, alanine and the like. In the present invention, a water-containing form, a hydrate and a solvate of each compound are also encompassed therein. [0109] In addition, the pyrazole compound represented by the above-mentioned formula 25 includes various isomers. For example, H N-NH N-N R1 and R1 forms are present as tautomers, and when an asymmetric carbon atom is present, enantiomers and diastereomers are present as stereoisomers based thereon. In some cases, geometric 10 WO 2005/095350 PCTIUS2005/009292 isomers may be present. Accordingly, the present invention encompasses all these isomers and mixtures thereof. [0110] The present invention also encompasses prodrugs and metabolites of the pyrazole compound represented by the formula. A "prodrug" is a derivative of the compound of the 5 present invention, which has a chemically or metabolically decomposable group, which, after being administered to a living organism, is restored to its original compound form and exhibits its intrinsic efficacy, and which includes complexes and salts free of a covalent bond. For example, ester derivatives known as prodrugs in the field of pharmaceutical agents can be used. 10 [0111] When the compound of the present invention is used as a pharmaceutical preparation, it is generally admixed with a pharmaceutically acceptable carrier, excipient, diluent, extender, disintegrant, stabilizer, preservative, buffer, emulsifier, fragrance, coloring agent, sweetening agent, thickening agent, corrigent, dissolution aids and other additives known per se, such as water, vegetable oil, alcohols such as ethanol, benzyl alcohol and the 15 like, polyethylene glycol, glycerol triacetate, gelatin, lactose, carbohydrates such as starch and the like, magnesium stearate, tale, lanolin, vaseline and the like, and produced in the form of tablet, pill, powder, granule, suppository, injection, eye drop, liquid, capsule, troche, aerosol, elixir, suspension, emulsion, syrup and the like by a conventional method for systemic or local, oral or parenteral administration. 20 [0112] While the dose of the compound of the present invention varies depending on the age, body weight, symptom, disease to be treated, administration method and the like, it is generally 1 mg to 1000 mg for an adult per administration, which is given once to several times a day. [01131 The compound of the present invention can be administered to a mammal (human, 25 mouse, rat, rabbit, dog, cat, bovine, pig, monkey etc.) as an HSD1 inhibitor, a prophylactic or therapeutic drug of diabetes, a prophylactic or therapeutic drug of diabetic complication (retinopathy, nephropathy, neuropathy, cardiac infarction and cerebral infarction based on arteriosclerosis etc.), a prophylactic or therapeutic drug of hyperlipemia, a prophylactic or therapeutic drug of obesity, neurodegenerative disease and the like, or a prophylactic or 30 therapeutic drug of diseases mediated by HSD1. [0114] The compound of the present invention can be administered to a mammal concurrently with other therapeutic drug of diabetes or obesity with the aim of the 10 WO 2005/095350 PCTIUS2005/009292 prophylaxis or treatment of diabetes. In the present invention, the "therapeutic drug of diabetes" encompasses therapeutic drugs of diabetic complications. Furthermore, the compound of the present invention can be administered in combination with other therapeutic drugs of diabetes or obesity to a mammal for the prophylaxis or treatment of obesity. 5 [0115] In the case of a combined administration, the compound of the present invention may be administered simultaneously with other therapeutic drugs of diabetes or other therapeutic drugs of obesity (hereinafter to be referred to as a combined pharmaceutical agent) or may be administered at time intervals. In the case of a combined administration, a pharmaceutical composition containing the compound of the present invention and a 10 combined pharmaceutical agent can be administered. Alternatively, a pharmaceutical composition containing the compound of the present invention and a pharmaceutical composition containing a combined pharmaceutical agent may be administered separately. The administration routes of respective pharmaceutical compositions may be the same or different. 15 [0116] In the case of a combined administration, the compound of the present invention may be administered at a dose of 1 mg to 1000 mg per administration, which is given once to several times a day. In addition, the compound may be administered at a smaller dose. The combined pharmaceutical agent can be administered at a dose generally employed for the prophylaxis or treatment of diabetes or obesity or at a smaller dose than that. 20 [0117] As other therapeutic drug of diabetes to be used for the combined administration, insulin preparation, sulfonylurea, insulin secretagogue, sulfonamide, biguanide, a glucosidase inhibitor, PTPlB inhibitor, insulin sensitizer and the like can be mentioned. For example, insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine 25 hydrochloride, voglibose, acarbose, pioglitazone hydrochloride and the like can be used for combined administration with the compound of the present invention. [0118] As other therapeutic drug of obesity to be used for the combined administration, for example, mazindol can be mentioned. [0119] One example of the production method of the pyrahole compound of the present 30 invention is described in the following, which does not limit the production method of the compound of the present invention. Even in the absence of description in the production method, efficient production can be afforded by introducing, where necessary, a protecting WO 2005/095350 PCTIUS2005/009292 group into a functional group followed by deprotection in a subsequent step, exchanging the order of respective production methods and steps, and the like. The post-reaction treatment can be applied by a typical method by selecting or combining conventional methods as necessary, such as isolation and purification, crystallization, recrystallization, silica gel 5 chromatography, preparative HPLC and the like. Production Method 1 [0120] In this production method, a pyrazole compound is produced, and the method includes any of the following steps. r2 R9 m n Ari + H 2 N NH 2

R

4

R

5 R R 2

R

3 (1) (2) Rs 8N-N 9 m A Ar

R

4

R

5

R

1

R

2

R

3 R7 (3) 10 wherein each symbol is as defined above. [0121] Diketone (1) synthesized by a known method and hydrazine hydrate (2) are reacted in a solvent to give pyrazole (3). As the solvent, methanol, ethanol, n-propanol, isopropanol, acetonitrile, diethyl ether, tetrahydrofuran (THF), acetic acid, 1,4-dioxane, N,N dimethylformamide, dimethyl sulfoxide, dichloromethane, 1,2-dichloroethane, chloroform, 15 benzene, chlorobenzene, o-dichlorobenzene, toluene, xylene, pyridine, acetic acid, or a mixed solvent thereof can be mentioned. The reaction temperature is preferably 20 0 C - 250 0 C. Examples [0122] The pyrazole compound represented by the formula of the present invention and the production method thereof are explained in detail in the following by referring to Examples, 20 which are not to be construed as limitative.

WO 2005/095350 PCTIUS2005/009292 Example 1-1: Production of 3-(2,4-dichlorophenyl)-4-methyl-5-((1-phenylcyclopropane)-1 yl)- pyrazole [0123] 1-(2,4-dichlorophenyl)-2-methyl-3-(1-phenylcyclopropane)-propane-1,3-dione (347 mg) were suspended in acetic acid (4 mL) and ethanol (2 mL), hydrazine hydrate (100 mg) 5 was added and the mixture was heated for 3 hours at 80 "C. The reaction solution was concentrated and extracted with ethyl acetate. The ethyl acetate layer was washed successively with saturated brine, dried over anhydrous sodium sulfate, and concentrated to dryness. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=3:1) and dried to give the title compound (318 mg). CH3+ H2N- NH2 CCH (1) (2) CI N--N CII H 10 (3) Examples 1-2 to 1-16: [0124] In the same manner as in Example 1-1, and using other conventional methods as necessary, a pyrazole compound was produced. The structural formula and property values of each Example compound are shown in the following Table. Example Molecular Structure 'H-NMR Ex.1-1 N-N (300MHz,DMSO-D6), 1.25-1.35(4H, m), 1.80(3H, s), 7.05-7.35(5H, m), 7.37-7.55(2H, m), 7.72(1H, s), 12.9(1H, brs) Ex.1-2 CI HN-N CI (300MHz,DMSO-D6), 2.93-3.12(4H, m), 6.54(1H, s), 7.19-7.48(5H, m), 7.66(1H, d, J=1.6Hz), 7.77(1H, d, C1 J=8.3Hz), 12.9(1H, brs)

'Y?

WO 2005/095350 PCTIUS2005/009292 Example Molecular Structure 'H-NMR Ex.1-3 CI HN-N C1 (300MTIz,CDC13), 1.83(3H, s), 2.93 2.97(2H, m), 3.06-3.11(2H, m), 7.11 7.18(3H, m), 7.27-7.38(3H, m), 7.48

CH

3 7.49(111, m) CI Ex.1-4 CI N-N (300MHz,DMSO-D6), 0.82-0.94(3H, m), 1.33-1.43(4H, m), 3.83-4.01(2H, m), 7.09-7.32(5H, m), 7.37-7.53(2H, m), 7.59-7.75(1H, m), 13.7(1H, brs)

CH

3 Ex.1-5 CI N_ (300MHz,DMSO-D6), 1.23-1.39(4H, m), 6.48(1H, brs), 7.13-7.39(5H, m), 7.40-7.54(1H, m), 7.61-7.72(1H, m), 7.72-7.90(1H, m), 13.0(1H, brs) C1" Ex. 1-6 NNH .AHF (300MHz,DMSO-D6), 0.96(3H, t, J=7.0Hz), 4.00(2H, q, J=7.0Hz), 4.26(2H, s), 7.04-7.76(7H, m), 13.5(1H, brs) (300MHz,DMSO-D6), 0.96(3H, t, J=7.0Hz), 4.00(2H, q, J=7.OHz), 4.26(2H, s), 7.04-7.76(7H, m), 13.5(1H, brs)

CH

3 Ex.1-7 C N- F (300MHz,DMSO-D6), 1.12-1.33(4H, m), 1.86-2.22(4H, m), 1.90(3H, s), 2.85-3.53(5H, m), 4.38-4.59(2H, m), 7.07-7.30(5H, m), 7.60(1H, dd, J=8.5, CH3 2.2Hz), 7.80(111, d, J=2.2Hz), C1 7.98(1H, d, J=8.5Hz), 10.8(1H, brs) Ex.1-8 C F (300MHz,DMSO-D6), 3.94-4.08(2H, m), 4.14-4.30(2H, m), 4.68(1H, t, J=5.0Hz), 7.05-7.81(7H, m), 12.7andl2.8(1H, each brs) C1J OH WO 2005/095350 PCTIUS2005/009292 Example Molecular Structure 'H-NMR Ex.1-9 H N- F (300MHz,DMSO-D6), 1.41(3H, s), 2.98(1H, d, J=15Hz), 3.01(1H, d, J=15Hz), 6.80-7.77(7H, m), 11.7(1H, brs) CIJ CH3 Ex.1-10 N- (300MHz,DMSO-D6), 1.32-1.41(4H, m), 1.80-2.03(4H, m), 1.98(3H, s), 2.94-3.10(1H, m), 3.28-3.49(4H, m), C o 7.14-7.23(3H, m),,7.26-7.33(2H, m), 8.46(1H, s), 8.47(1H, s) C1 Ex.1-11 N- (300MHz,DMSO-D6), 1.10-1.33(4H, m), 1.74-1.98(4H, m), 1.84(3H, s), 2.67-2.96(3H, m), 3.69-3.91(2H, m), c o 6.91-7.31(6H, m), 7.78(1H, d, J=7.7Hz), 8.21(1H, d, J=4.8Hz), 12.1and12.3(1H, each s) Ex.1-12 H F (400MHz,CDC13), 0.97(6H, d, J=7.19Hz), 1.26-1.32(2H, m), 1.42 1.47(2H, m), 3.04(1H, septet, J7.19Hz), 6.89-6.96(3H, m), 7.05 7.10(1H, m), 7.35-7.44(5H, m) Ex.1-13 H F (300MIfz,DMSO-D6), 1.18-1.34(4H, m), 1.73 and 1.82(3H, each s), 7.02 7.22(4H, m), 7.34-7.62(4H, m), 12.6 and 12.9(1H, each s) Ex.1-14 CI N-N (300MHz,DMSO-D6), 1.20-1.36(4H, m), 1.84 and 1.91(3H, each s), 0 4.08(2H, t, J=9.0Hz), 4.44(2H, t, J=9.OHz), 7.08-7.20(3H, m), 7.22 N' /a7.30(2H, m), 7.50-7.66(3H, m), 12.6 and 12.9(1H, each s) A4 WO 2005/095350 PCTIUS2005/009292 Example Molecular Structure 1 H-NMR Ex.1-15 H F (400MI-Hz,DMSO-D6), 1.22-1.35(4H, m), 2.14 and 2.26(3H, each s), 6.99 N 7.17(4H, in), 7.18-7.32(1H, in), 7.72 7.94(2H, in), 8.49-8.63(1H, m), 12.9(1H, brs) CH3 Ex.1-16 F H F (400MHz,DMSO-D6), 1.08-1.36(8H, N-N rm), 1.72(3H, s), 6.98-7.16(8H, mn), 7.37-7.55(2H, in), 12.4(1H, brs)

CH

3 Experimental Example: in vitro HSD1 (hydroxysteroid dehydrogenase 1) activity inhibitory action [0125] The HSD1 inhibitory activity was examined by quantitative determination by an 5 SPA (scintillation proximity assay) system of the suppressive action on the conversion from cortisone to cortisol using human HSD1 (hereinafter recombinant HSD1) expressed using a baculo-virus system as an enzyme source. For the reaction, a reagent was added to a 96 well plate (96 well Opti-platesTm-96 (Packard)) to the following final concentration and a volume of 100 pl was reacted at room temperature for 90 min. The reaction solution used was 0.1 10 pg/mL recombinant HSD1, 500 AM NADPH, 16 nM 3 H cortisone (Amersham Biosciences, 1.78 Tbq/mol) dissolved in 0.1% BSA (Sigma)-containing PBS and the test drug was 2 p4l of a compound solution (dissolved in DMSO). After 90 min, the reaction was stopped by adding PBS (40 Al, containing 0.1% BSA (Sigma)) containing 0.08 pg of anti-cortisol mouse monoclonal antibody (East Coast Biologics), 365 pg SPA PVT mouse antibody-binding 15 beads (Amersham Biosciences) and 175 AM carbenoxolone (Sigma) to the reaction solution. After the completion of the reaction, the plate was incubated overnight at room temperature and the radioactivity was measured by Topcount (Packard). For control, the value (0% inhibition) of the well containing 2 pl of DMSO instead of the test drug was used, and for positive control, the value (100% inhibition) of the well containing carbenoxolone instead of 20 the test drug at the final concentration of 50 pM was used. The inhibition (%) of the test drug was calculated by ((value of control - value of test drug)/(value of control - value of positive control)) x 100 (%). The IC 50 value was analyzed using a computer-based curve fitting soft. The obtained results are shown in the following Table.

WO 2005/095350 PCTIUS2005/009292 Examples Human HSD1 IC 50 Ex.1-1 ++ Ex.1-2 + Ex.1-3 ++ Ex.1-4 + Ex.1-5 + Ex.1-6 + Ex.1-7 + Ex.1-8 + Ex.1-9 + Ex.1-10 + Ex.1-11 ++ Ex.1-12 ++ Ex.1-13 ++ Ex.1-14 + Ex.1-15 ++ Ex.1-16 ++ [0126] In the above Table, "+" in the column of IC 50 means l0nM; IC 5 o<1,000nM and "++" in the column of ICso means ICso < OnM. Examples 2-1 to 2-45: 5 [0127] In the same manner as in Example 1-1, and using other conventional methods as necessary, the pyrazole compounds shown in the following Table can be also produced. F F H Cl H N-N N-N Ex.2-1 Ex.2-2 CF3 F F N-N N-N Ex.2-3 Ex.2-4 OMe WO 2005/095350 PCTIUS2005/009292 C I H /l N-N Ex.2-5 \ /Ex.2-6Z FOHH FF N-N Ex.2-7 /Ex.2-8

OH

3

H

3

CO

3 3 H F

N-N

7x2- Ex.2-1O

CH

3 OeH.

3 C OH 3 H CI H /N N-N H/ E.-1Ex.2-12 I>

OH

3 CH3 OH 3 ci H H N-N ii\ci H Ex.2-13 /\ /7 S Ex.2-14

CH

3 H ci -H 7L H 7L Ex.2-15 Ex.2-.16 0

OH

3 N H 3 H F\ H F N-N N-N Ex.2-17 Ex.2-18\ 7 N OH 3 N H 3 0 HF HF N-N N-N / Ex.2- 19 I" -'Ex.2-20 / 'N H 3 N--: OH 3

H

3 C HN,, n17 WO 2005/095350 PCTIUS2005/009292 F F N-N N-N EX.2-21 NIEx.2-22 N CH N CH 3 CH,> H / HF N-N N-N Ex.2-23 N \ 17 Ex.2-24 /\/ SC1,,C N - C H 3 00 FF H FH N-N IN-N / Ex.2-25Ex.2-26 0 2 N - O 3

H

2 N CH HH Ex.2-27 / y Z Ex.2-28 0

H

3 0 l N -O 3

H

3 eII"N C - s H HHOHH H F H 7HH N-N

HZ'N

iEx.2-29 Z' ~E.-0' ,

H

3 OE.23 O H 3 - C H 3

H

3 CF

H

3 -0 H F CF 3 \0 H 7 Ex.2-31 / -- Ex.2-32 / 'K

OH

3 OH 3 H3H -N

IHOH

3 00 F F H 7~H N-N N-N " EX.2-35 , KEx.2-36 H 'Kl

H

2 N I H 3 C 3

H

3 00 ')2 WO 2005/095350 PCTIUS2005/009292 F F H H N-N N-N Ex.2-37 Ex.2-42

H

3 CO OCH 3

CH

3 0O F F Ex.2-39 C'- N H- / E.-40H N-N N-N

CH

3 CH 3 FF C1 H F N-N N-N Ex.2-41 /7 Ex.2-42 O3 CH 0 O' CH 3 H3.NCH 3 H F~ HPF N-N N-N Ex.2-43 /yEx.2-44/7 0 %o

H

3 C-ff OH 3

CH

3 0 F H N-N Ex.2-45 Z 0 OH 3 [01281 As mentioned above, the pyrazole compound of the present invention has superior HSD 1 inhibitory activity and is useful as an HSD 1 inhibitor, a therapeutic drug of diabetes or a therapeutic drug of obesity. 5

Claims (9)

13. A method for the treatment or prophylaxis of metabolic syndrome, 2 which comprises administering an effective amount of the pyrazole compound of claim 1, a 3 prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal. 1 14. The method of claim 11, wherein a different therapeutic drug of 2 diabetes is used in combination. 1 15. The method of claim 14, wherein the different therapeutic drug of 2 diabetes is one or more pharmaceutical agents selected from the group consisting of an 3 insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an a 4 glucosidase inhibitor, a PTP1B inhibitor and an insulin sensitizer. 1 16. The method of claim 15, wherein the different therapeutic drug of 2 diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, .3 glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, 4 gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, 5 voglibose, acarbose and pioglitazone hydrochloride. 1 17. The method of claim 12, wherein a different therapeutic drug of 2 diabetes is used in combination. WO 2005/095350 PCTIUS2005/009292 1 18. The method of claim 17, wherein the different therapeutic drug of 2 diabetes is one or more pharmaceutical agents selected from the group consisting of an 3 insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an 4 glucosidase inhibitor, a PTPlB inhibitor and an insulin sensitizer. 1

19. The method of claim 18, wherein the different therapeutic drug of 2 diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, 3 glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, 4 gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, 5 voglibose, acarbose and pioglitazone hydrochloride. 1

20. The method of claim 13, wherein a different therapeutic drug of 2 diabetes is used in combination. 1

21. The method of claim 20, wherein the different therapeutic drug of 2 diabetes is one or more pharmaceutical agents selected from the group consisting of an 3 insulin preparation, a sulfonylurca, an insulin secretagogue, a sulfonamide, a biguanide, an o 4 glucosidase inhibitor, a PTPIB inhibitor and an insulin sensitizer. 1

22. The method of claim 21, wherein the different therapeutic drug of 2 diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, 3 glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, 4 gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, 5 voglibose, acarbose and pioglitazone hydrochloride. 1

23. The method of claim 11, wherein a different therapeutic drug of 2 obesity is used in combination. 1

24. The method of claim 23, wherein the different therapeutic drug of 2 obesity is Mazindol. 1

25. The method of claim 12, wherein a different therapeutic drug of 2 obesity is used in combination. 1

26. The method of claim 25, wherein the different therapeutic drug of 2 obesity is Mazindol. 1'7 WO 2005/095350 PCT/US2005/009292 1 27. The method of claim 13, wherein a different therapeutic drug of 2 obesity is used in combination. 1 28. The method of claim 27, wherein the different therapeutic drug of 2 obesity is Mazindol.